Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

PURPOSE To evaluate the prognostic role of soluble CD163 (sCD163) in serum and macrophage infiltration in primary melanomas from patients with American Joint Committee on Cancer (AJCC) stage I/II melanoma. The scavenger receptor CD163 is associated with anti-inflammatory macrophages, and it is shed from their surface. PATIENTS AND METHODS Serum samples from 227 patients with stage I/II melanoma obtained before definitive surgery (baseline) and during 5 years of follow-up were analyzed for sCD163 by enzyme-linked immunosorbent assay. Excised formalin-fixed, paraffin-embedded primary melanomas from 190 patients were available for immunohistochemical analyzes of CD163(+) and CD68(+) macrophage infiltration. They were estimated semiquantitatively in three different tumor compartments: tumor nests, tumor stroma, and at the invasive front of the tumor. RESULTS Serum sCD163 treated as an updated continuous covariate as well as the baseline value were analyzed together with the covariate's ulceration and thickness in a Cox proportional hazards model. sCD163 was an independent prognostic factor for overall survival (baseline, hazard ratio [HR] = 1.4; 95% CI, 1.1 to 1.7; P = .01; and updated, HR = 1.4; 95% CI, 1.1 to 1.8; P = .003). Melanomas with dense CD163(+) macrophage infiltration in tumor stroma and CD68(+) macrophage infiltration at the invasive front were associated with poor overall survival (CD163, HR = 2.7; 95% CI, 0.8 to 9.3; P = .11; and CD68, HR = 2.8; 95% CI, 1.2 to 6.8; P = .02) independent (borderline for CD163) of thickness and ulceration. CONCLUSION Both serum levels of sCD163 and the presence of CD68(+) macrophage infiltration at the tumor invasive front are independent predictors of survival in AJCC stage I/II melanoma. CD163(+) cell infiltration in tumor stroma may be predictive of survival.

[1]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[2]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[3]  Robert J. Marinelli,et al.  Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas , 2008, Clinical Cancer Research.

[4]  S. Moestrup,et al.  New immunological serum markers in bacteraemia: anti‐inflammatory soluble CD163, but not proinflammatory high mobility group‐box 1 protein, is related to prognosis , 2008, Clinical and experimental immunology.

[5]  William M. Lee,et al.  Soluble CD163 from activated macrophages predicts mortality in acute liver failure. , 2007, Journal of hepatology.

[6]  T. Ichim,et al.  Stem Cell Therapy for Autism , 2007, Journal of Translational Medicine.

[7]  S-J Guo,et al.  Tumor-associated macrophages and CD3-ζ expression of tumor-infiltrating lymphocytes in human esophageal squamous-cell carcinoma. , 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[8]  J. Tímár,et al.  Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma , 2007, Pathology & Oncology Research.

[9]  J. Suttles,et al.  IL-12 Rapidly Alters the Functional Profile of Tumor-Associated and Tumor-Infiltrating Macrophages In Vitro and In Vivo1 , 2007, The Journal of Immunology.

[10]  S. Moestrup,et al.  Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163* , 2006, Critical care medicine.

[11]  S. Moestrup,et al.  CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. , 2006, Immunobiology.

[12]  S. Vogel,et al.  Pivotal Advance: Activation of cell surface Toll‐like receptors causes shedding of the hemoglobin scavenger receptor CD163 , 2006, Journal of leukocyte biology.

[13]  N. Araki,et al.  AM-3K, an Anti-macrophage Antibody, Recognizes CD163, a Molecule Associated with an Anti-inflammatory Macrophage Phenotype , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  K. E. Matthews,et al.  Expression of the hemoglobin-haptoglobin receptor CD163 on hematopoietic progenitors. , 2006, Stem cells and development.

[15]  S. Moestrup,et al.  The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. , 2006, Atherosclerosis.

[16]  J. Melkko,et al.  Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.

[17]  Luigi Minerba,et al.  The predictive value of CD8, CD4, CD68, and human leukocyte antigen‐D‐related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase , 2005, Cancer.

[18]  Julie R. Carrington,et al.  Volume Index , 2005, European journal of haematology.

[19]  Tudung T Nguyen,et al.  Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage , 2005, The American journal of surgical pathology.

[20]  P. Chu,et al.  CD163: a specific marker of macrophages in paraffin-embedded tissue samples. , 2004, American journal of clinical pathology.

[21]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[22]  Natale Cascinelli,et al.  An Evidence‐based Staging System for Cutaneous Melanoma 1 , 2004, CA: a cancer journal for clinicians.

[23]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[24]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[25]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[26]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[27]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[28]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[29]  M. Nakagawa,et al.  Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.

[30]  T. Langmann,et al.  The Scavenger Receptor CD163: Regulation, Promoter Structure and Genomic Organization , 2000, Pathobiology.

[31]  T. Langmann,et al.  Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro‐ and antiinflammatory stimuli , 2000, Journal of leukocyte biology.

[32]  L. Akslen,et al.  Significance of tumour‐associated macrophages, vascular endothelial growth factor and thrombospondin‐1 expression for tumour angiogenesis and prognosis in endometrial carcinomas , 1999, International journal of cancer.

[33]  P. Högger,et al.  Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. , 1999, Biochemical and biophysical research communications.

[34]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[35]  S. Pileri,et al.  PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. , 1993, The American journal of pathology.

[36]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[37]  A. Griffioen,et al.  Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma , 2007, Cancer Immunology, Immunotherapy.

[38]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.